HC Wainwright Brokers Decrease Earnings Estimates for Cybin

Key Points

• HC Wainwright has revised its earnings estimates for Cybin, forecasting a Q2 2026 loss of ($0.74) per share, down from a prior estimate of ($0.56).
• Institutional investors have increased their stakes in Cybin, with 17.94% of the stock currently owned by institutional investors, indicating growing confidence in the company.
• Cybin's stock has a consensus rating of "Buy" with a price target of $85.00, despite recent earnings estimate downgrades.

Cybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Cybin in a report released on Monday, August 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.74) per share for the quarter, down from their previous estimate of ($0.56). The consensus estimate for Cybin's current full-year earnings is ($4.76) per share. HC Wainwright also issued estimates for Cybin's Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($1.57) EPS, FY2029 earnings at $5.17 EPS and FY2030 earnings at $7.47 EPS.

CYBN has been the subject of several other research reports. Cantor Fitzgerald raised Cybin to a "strong-buy" rating in a research report on Tuesday, May 13th. Canaccord Genuity Group cut their price target on Cybin from $73.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company's stock. According to MarketBeat.com, Cybin has an average rating of "Buy" and a consensus price target of $85.00.

Cybin Price Performance

Shares of NYSE CYBN traded up $0.23 during trading hours on Wednesday, hitting $7.15. 592,928 shares of the company's stock were exchanged, compared to its average volume of 320,405. Cybin has a 1-year low of $4.81 and a 1-year high of $13.88. The stock has a market capitalization of $168.67 million, a price-to-earnings ratio of -1.63 and a beta of 0.68. The company's 50-day moving average price is $7.68 and its 200-day moving average price is $7.55.

Institutional Investors Weigh In On Cybin

A number of institutional investors have recently added to or reduced their stakes in the stock. Cowa LLC grew its stake in shares of Cybin by 12.8% in the 2nd quarter. Cowa LLC now owns 13,200 shares of the company's stock valued at $111,000 after purchasing an additional 1,500 shares during the period. AdvisorShares Investments LLC grew its position in Cybin by 3.2% in the fourth quarter. AdvisorShares Investments LLC now owns 50,651 shares of the company's stock valued at $447,000 after acquiring an additional 1,567 shares during the period. National Bank of Canada FI raised its stake in Cybin by 3,546.5% during the first quarter. National Bank of Canada FI now owns 5,251 shares of the company's stock worth $33,000 after acquiring an additional 5,107 shares in the last quarter. Knott David M Jr lifted its holdings in shares of Cybin by 10.6% during the first quarter. Knott David M Jr now owns 66,880 shares of the company's stock valued at $424,000 after acquiring an additional 6,434 shares during the period. Finally, Boothbay Fund Management LLC lifted its holdings in shares of Cybin by 9.2% during the fourth quarter. Boothbay Fund Management LLC now owns 106,665 shares of the company's stock valued at $941,000 after acquiring an additional 9,029 shares during the period. 17.94% of the stock is owned by institutional investors and hedge funds.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.